Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Solymbic

- PMLiVE

NICE backs three ulcerative colitis treatments

Remicade, Simponi and Humira recommended for NHS reimbursement

- PMLiVE

Amgen sets premium price for Blincyto

Leukaemia drug becomes one of the most expensive pharma products on the market

- PMLiVE

First biosimilar Humira launches in India

AbbVie to face competition for world’s biggest-selling drug

- PMLiVE

Amgen’s Xgeva cleared in US for rare bone cancer complication

Hypercalcaemia of malignancy affects around 2.7% of cancer patients

- PMLiVE

New ASPIRE data boosts Amgen’s Kyprolis

Trial results presented at ASH show drug can be safely added to standard chemotherapy

EU flag

Life expectancy continues to rise in Europe

EC report shows five-year improvement since 1990

- PMLiVE

Early approval for Amgen’s breakthrough leukaemia drug

32% of patients in remission after at least four weeks of Blincyto infusion

- PMLiVE

Novartis’ heart failure drug on EMA’s fast track

Candidate is the first cardiovascular drug to get accelerated review in the EU

- PMLiVE

The biosimilars are coming

Lilly on navigating the regulatory pathway for its insulin glargine

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

- PMLiVE

Deaths cause Amgen to drop stomach cancer drug

Increase in patient mortality in patients taking rilotumumab during trial

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links